Drug intelligence / Profile preview

PF-1805

Development stage: Preclinical
Lead developer: ImmunoForge
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

PF-1805 is a recombinant polypeptide drug candidate developed by Immunoforge. It acts as a modulator of NPRL2 (NPR2-like, GATOR1 complex subunit) and targets the natriuretic peptide receptor B (NPR-B). The drug is being investigated primarily for the treatment of achondroplasia, a congenital disorder characterized by abnormal bone growth. Its mechanism involves modulation of NPRL2/NPR-B signaling pathways, which are implicated in skeletal development. PF-1805 utilizes Immunoforge's half-life extension platform technology to enable weekly dosing and potentially improve therapeutic outcomes in patients with achondroplasia[1][3].

Targets

NPR2 (C-type Natriuretic Peptide Receptor B)NPRL2 (Nitrogen permease regulator 2-like protein)

Beyond the preview

Go deeper on PF-1805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-1805.

Explore the full profile